FDA Brief

Warning letters Drugs

FDA warning letter to

Global Life Technologies Corp.

High riskIssued Feb 6, 2024Posted Feb 13, 2024Center for Drug Evaluation and Research | CDER

FDA warns Global Life Technologies over unapproved Nozin Nasal Sanitizer claims, including infection prevention and inside-nostril use.

What happened

FDA reviewed the Nozin website on October 19 and 20, 2023, and related Facebook and X/Twitter pages. FDA found Nozin Nasal Sanitizer marketed as an OTC topical antiseptic with claims that it kills pathogenic bacteria, reduces infection risk from MRSA and COVID-19, lasts up to 12 hours, and is applied inside the nostrils. FDA concluded the product is an unapproved new drug and misbranded because it lacks an approved application and does not meet the OTC monograph conditions.

What FDA found

  1. FDA says Nozin Nasal Sanitizer is a new drug sold without an FDA-approved application and is not generally recognized as safe and effective for its labeled uses.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. FDA says the product is misbranded because it is a nonprescription drug that does not meet the requirements for marketing under section 505G and has no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
  3. Labeling claims that the product helps prevent infection or disease from COVID-19, MRSA, or MSSA go beyond the general antiseptic use allowed by the OTC rules.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3); 1994 TFM
  4. Labeling claims that the product works for up to 12 hours are not allowed under the OTC tentative final monograph for antiseptics.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3); 1994 TFM
  5. The labeling says the product is applied inside the nostrils, which is not permitted for consumer or health care antiseptics under the OTC rules.

    1994 TFM, as amended; section 505G(a)(3) of the FD&C Act

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the specific steps taken to correct the violations, with explanations and supporting documents. If correction cannot be completed in that time, the company must state the reason and when it will be completed.

Who should pay attention

  • OTC drug marketers that make antiseptic or infection-prevention claims
  • retailers and distributors selling nasal antiseptic products
  • companies using OTC monograph pathways for topical antiseptics

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk